MARKET

KNTE

KNTE

Kinnate Biopharma Inc.
NASDAQ
2.660
0.000
0.00%
After Hours: 2.660 0 0.00% 17:53 03/28 EDT
OPEN
2.660
PREV CLOSE
2.660
HIGH
2.690
LOW
2.650
VOLUME
518.48K
TURNOVER
0
52 WEEK HIGH
7.19
52 WEEK LOW
1.040
MARKET CAP
125.46M
P/E (TTM)
-0.9583
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at KNTE last week (0318-0322)?
Weekly Report · 3d ago
XOMA Corp Entered Into A Merger Agreement To Acquire Kinnate Biopharma For A Base Cash Price Per Share Of $2.3352 Per Share And An Additional Cash Amount Of Not More Than $0.2527 Per Share
XOMA Corporation has entered into a merger agreement to acquire Kinnate Biopharma Inc. The acquisition is expected to close in April 2024. XOMA has extended the Offer's expiration date to April 2, 2024. Kinnate stockholders will receive an additional cash amount of up to $0.2527 per share.
Benzinga · 03/19 20:15
*XOMA: Cash Amount That Kinnate Stockholders Will Receive in Offer Is $2.5879 Per Shr >XOMA
Dow Jones · 03/19 20:13
*XOMA to Pay Base Cash Price of $2.3352 Per Shr of Kinnate and Additional Cash Amount of Not More Than $0.2527 Per Shr, Plus One Non-Tradeable CVR
Dow Jones · 03/19 20:12
*XOMA to Acquire Kinnate Biopharma >XOMA KNTE
Dow Jones · 03/19 20:11
Weekly Report: what happened at KNTE last week (0311-0315)?
Weekly Report · 03/18 09:08
Kinnate Biopharma Inc <KNTE.OQ> expected to post a loss of 44 cents a share - Earnings Preview
Kinnate Biopharma Inc expected to post a loss of 44 cents a share. The company is expected to show change in quarterly revenue when it reports results on March 18. The average analyst rating on the shares is "buy" and the median 12-month price target is $2.50.
Reuters · 03/15 21:25
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
Former Attorney General of Louisiana Charles C. Foti, Jr. And the law firm of Kahn Swick & Foti are investigating the proposed sale of Kinnate Biopharma Inc. To XOMA Corporation. KSF is seeking to determine whether the consideration undervalues the Company.
Barchart · 03/13 10:49
More
About KNTE
Kinnate Biopharma Inc. is a clinical-stage precision oncology company. It is focused on the discovery, design and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its lead product candidate is exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma and other solid tumors. Its second product candidate is KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC). KIN-3248 is designed to address clinically observed kinase domain mutations in FGFR2 and FGFR3. It is also advancing other small molecule research programs, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor in its KIN004 program for the treatment of ovarian carcinoma (OC), triple-negative breast cancer (TNBC) and metastatic castration-resistant prostate cancer (mCRPC).

Webull offers Kinnate Biopharma Inc stock information, including NASDAQ: KNTE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KNTE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KNTE stock methods without spending real money on the virtual paper trading platform.